Structure-activity relationships of benzoxazolinones with respect to auxin-induced growth and auxin-binding protein
摘要:
The structure-activity relationships of the naturally occurring auxin-inhibiting substance, 6-methoxy-2-benzoxazolinone, isolated from maize shoots, and its artificial analogues with respect to auxin activity and membrane-bound auxin-binding protein, were studied. 6-Isobutoxy-2-benzoxazolinone strongly inhibited auxin (1-naphthylacetic acid, NAA)-induced growth of etiolated maize coleoptile segments. 6-Isopropoxy-2-benzoxazolinone, 6-ethoxy-2-benzoxazolinone and 6-methoxy-2-benzoxazolinone showed significant inhibitory activity. However, 2-benzoxazolinone and 6-benzyloxy-2-benzoxazolinone did not inhibit auxin-induced growth. On the basis of these data, it seemed reasonable to assume that the auxin-inhibitory activity was enhanced by increasing the side chain length at position C-6 on the 2-benzoxazolinone, although the attachment of a ring at C-6 destroyed activity. Competition by benzoxazolinones with an alkoxy group at C-6 with H-3-NAA at auxin-binding protein(s) isolated from endoplasmic reticulum (ER) membrane of maize shoots showed a positive correlation with their physiological effects. However, since the inhibitory activity of the benzoxazolinones for auxin-receptor(s) binding was small compared with their physiological activity, the benzoxazolinones may contribute to inhibition of auxin-induced growth through interference with other auxin-receptors.
申请人:Board of Regents, The University of Texas System
公开号:US20160060260A1
公开(公告)日:2016-03-03
Disclosed herein are compounds and compositions useful in the treatment of bromodomain-containing protein-mediated diseases, such as cancer, having the structure of Formula I:
Methods of inhibiting activity of a bromodomain-containing protein in a human or animal subject are also provided.
Catalytic S
<sub>N</sub>
Ar Hydroxylation and Alkoxylation of Aryl Fluorides
作者:Qi‐Kai Kang、Yunzhi Lin、Yuntong Li、Lun Xu、Ke Li、Hang Shi
DOI:10.1002/anie.202106440
日期:2021.9.6
mechanism of SNAr reactions involving metal arene complexes is hypothesized to involve a stepwise pathway (addition followed by elimination), experimental data that support this hypothesis is still under exploration. Mechanistic studies and DFTcalculations suggest either a stepwise or stepwise-like energy profile. Notably, we isolated a rhodium η5-cyclohexadienyl complex intermediate with an sp3-hybridized
亲核芳香取代 (S N Ar) 是一种通过用亲核试剂取代离去基团将杂原子结合到芳香环中的强大策略,但这种方法仅限于缺电子芳烃。我们现在已经建立了一种通过催化 S N Ar 反应获取苯酚和苯基烷基醚的可靠方法。该方法适用于广泛的富电子和中性芳基氟化物,它们在经典的 S N Ar 条件下呈惰性。虽然 S N的机制假设涉及金属芳烃配合物的 Ar 反应涉及逐步途径(添加后消除),支持该假设的实验数据仍在探索中。机械研究和 DFT 计算表明了一个逐步或逐步的能量分布。值得注意的是,我们分离了铑 η 5 -环己二烯基复合中间体,其具有带有亲核试剂和离去基团的 sp 3 -杂化碳。
[EN] SUBSTITUTED PYRROLIDINES AND THEIR USE<br/>[FR] PYRROLIDINES SUBSTITUÉES ET LEUR UTILISATION
申请人:ABBVIE SARL
公开号:WO2019193062A1
公开(公告)日:2019-10-10
The invention discloses compounds of Formula (I) wherein R1, R2, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
Oral care compositions with color changing indicator
申请人:Sabnis W. Ram
公开号:US20060222601A1
公开(公告)日:2006-10-05
The invention describes color changing toothpastes and mouthwashes which contains acid-base indicator(s) for interaction with the oral cavity to provide a color change indicative of treatment time.
这项发明描述了含有酸碱指示剂的变色牙膏和漱口水,用于与口腔相互作用,以提供治疗时间的颜色变化指示。
COMPOUNDS FOR TREATING INFECTIOUS DISEASES
申请人:Whatehead Institute for Biomedical Research
公开号:US20150284356A1
公开(公告)日:2015-10-08
The present invention provides compounds of Formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting fungal or parasitic growth. The compounds are useful as inhibitors of glycosylphosphatidylinositol (GPI)-anchor biosynthesis, in particular, as inhibitors of fungal Gwt1 activity. The present invention further provides methods of using the compounds described herein for treating fungal or parasitic infections. The compounds can also be used as biological probes to study the effects of inhibiting Gwt1 activity.